title: Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.
abstract: Replication-defective adenovirus type 5 (Ad5) vector-based vaccines are widely known to induce strong immunity against immunodeficiency viruses. To exploit this immunogenicity while overcoming the potential problem of preexisting immunity against human adenoviruses type 5, we developed a recombinant chimeric adenovirus type 5 with type 35 fiber vector (rAd5/35). We initially produced a simian immunodeficiency virus (SIV) gag DNA plasmid (rDNA-Gag), a human immunodeficiency virus type 1 (HIV-1) 89.6 env DNA plasmid (rDNA-Env) and a recombinant Ad5/35 vector encoding the SIV gag and HIV env gene (rAd5/35-Gag and rAd5/35-Env). Prime-boost vaccination with rDNA-Gag and -Env followed by high doses of rAd5/35-Gag and -Env elicited higher levels of cellular immune responses than did rDNAs or rAd5/35s alone. When challenged with a pathogenic simian human immunodeficiency virus (SHIV), animals receiving a prime-boost regimen or rAd5/35s alone maintained a higher number of CD4(+) T cells and remarkably suppressed plasma viral RNA loads. These findings suggest the clinical promise of an rAd5/35 vector-based vaccine.
authors.affiliation: Department of Virology III, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan. someyan@nih.go.jp
authors.forename: Kenji
authors.initials: K
authors.lastname: Someya
authors.forename: Ke-Qin
authors.initials: KQ
authors.lastname: Xin
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Ami
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Izumi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Mizuguchi
authors.forename: Shinrai
authors.initials: S
authors.lastname: Ohta
authors.forename: Naoki
authors.initials: N
authors.lastname: Yamamoto
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Honda
authors.forename: Kenji
authors.initials: K
authors.lastname: Okuda
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology; D018791:CD4 Lymphocyte Count; D004195:Disease Models, Animal; D015683:Gene Products, gag / Q000235:genetics / Q000276:immunology*; D005822:Genetic Vectors; D000882:Haplorhini; D006801:Humans; D012367:RNA, Viral / Q000097:blood; D018449:SAIDS Vaccines / Q000276:immunology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology; D019562:Viral Load; D054299:env Gene Products, Human Immunodeficiency Virus / Q000235:genetics / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D000914:Antibodies, Viral; D000956:Antigens, Viral; D015683:Gene Products, gag; D012367:RNA, Viral; D018449:SAIDS Vaccines; D054299:env Gene Products, Human Immunodeficiency Virus; C115853:simian immunodeficiency virus gag p55